A Novel Intervention for Patients With Cancer

Sponsor
Dana-Farber Cancer Institute (Other)
Overall Status
Recruiting
CT.gov ID
NCT05643027
Collaborator
National Cancer Institute (NCI) (NIH)
20
1
1
10.9
1.8

Study Details

Study Description

Brief Summary

This research study is being done to develop an intervention for psychological symptoms that patients diagnosed with cancer may experience. Psychological symptoms may include thoughts, feelings, emotions, and memories

The names of the study intervention and research activities involved in this study are/is:
  • Acceptance & Commitment Therapy (ACT) for Cancer (involving 6 sessions with a licensed clinical psychologist)

  • Questionnaires

  • Post-study interview

Consistent with the NIH Stage Model for Behavioral Intervention Development, the investigators have adapted an existing, empirically-validated intervention, Acceptance and Commitment Therapy (ACT), to address substance use disorder risk during cancer care. The core components of ACT are particularly well-suited to address the psychological processes underlying opioid misuse in individuals treated for cancer pain. The overarching aim is to assess the feasibility and acceptability of the intervention by conducting a randomized pilot trial of the revised intervention ("ACTION") for cancer patients on opioid therapy, and at risk for SUD.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Acceptance and Commitment Therapy
N/A

Detailed Description

This research study is a Feasibility Study, which is the first-time investigators are examining this psychological intervention in patients with cancer who are prescribed opioids and are receiving palliative care. This study is being conducted to develop a psychological intervention designed specifically for individuals with cancer. The purpose of this study is to determine how practical this intervention is, to determine patient satisfaction, and test the study procedures. The aims are to:

  1. determine whether this intervention will be appropriate for further testing;

  2. identify which parts of the protocol and procedures need to be modified; and

  3. assess patients' reactions to this intervention.

This research study involves a psychological intervention for thoughts, feelings, emotions, and memories that individuals diagnosed with cancer may have.

The names of the study intervention and research activities involved in this study are/is:
  • Acceptance & Commitment Therapy (ACT) for Cancer (involving 6 sessions with a licensed clinical psychologist)

  • Questionnaires

  • Post-study interview

The research study procedures include: screening for eligibility and study treatment including evaluations, 6 visits, and a post-study interview.

Participants will be on this research study for up to 2 months.

It is expected that about 10 people will take part in this research study

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
A Novel Intervention for Avoidance-Related Opioid Misuse in Patients With Cancer
Anticipated Study Start Date :
Feb 1, 2023
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Other: INTERVENTION FOR AVOIDANCE-RELATED OPIOID MISUSE

Participants will participate in a six-session behavioral intervention, delivered by a licensed clinical psychologist.

Behavioral: Acceptance and Commitment Therapy
Six-session, skills-based behavioral intervention targeting risk factors for opioid use disorder in the context of cancer

Outcome Measures

Primary Outcome Measures

  1. Feasibility and acceptability of the intervention, as reported on semi-structured exit interviews [1 year]

    exit interviews for qualitative feedback from research participants

Secondary Outcome Measures

  1. Feasibility and acceptability of the intervention, as reported on the client satisfaction questionnaire - 8 (CSQ-8) [1 year]

    patient-reported satisfaction on the CSQ-8; higher scores indicate higher levels of satisfaction but some items are reverse-scored

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • at least 18 years old

  • have an estimated survival time of at least 6 months (as estimated by palliative care provider)

  • score at least 4 on the Opioid Risk Tool (ORT)

  • have been diagnosed with any cancer, including hematologic malignancies

  • performance status criterion of 0, 1, or 2 [ with 0 indicating that the patient is asymptomatic, 1 that the patient is symptomatic but fully ambulatory, and 2 that the patient is symptomatic and in bed <50% of the day]

Exclusion Criteria:
  • Patients with a score at least 3 to ensure that all enrolled patients are able to participate in the intervention, complete assessments, ensure that no patients who are too sick to participate are enrolled; this will enhance the rigor of the study)

  • currently be on opioid therapy

  • not meet criteria for current substance use disorder

  • assessed by the Diagnostic & Statistical Manual of mental disorders; DSM-5 or be receiving substance use disorder treatment; and speak and comprehend English sufficiently to be able to participate in psychotherapy.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Dana Farber Cancer Institute Boston Massachusetts United States 02215

Sponsors and Collaborators

  • Dana-Farber Cancer Institute
  • National Cancer Institute (NCI)

Investigators

  • Principal Investigator: Miryam Yusufov, PhD, Dana-Farber Cancer Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Miryam Yusufov, PhD, Principal Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT05643027
Other Study ID Numbers:
  • 21-587
  • 1K08CA259538-01A1
First Posted:
Dec 8, 2022
Last Update Posted:
Dec 8, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Miryam Yusufov, PhD, Principal Investigator, Dana-Farber Cancer Institute
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 8, 2022